SE9402430L - Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten - Google Patents
Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugatenInfo
- Publication number
- SE9402430L SE9402430L SE9402430A SE9402430A SE9402430L SE 9402430 L SE9402430 L SE 9402430L SE 9402430 A SE9402430 A SE 9402430A SE 9402430 A SE9402430 A SE 9402430A SE 9402430 L SE9402430 L SE 9402430L
- Authority
- SE
- Sweden
- Prior art keywords
- conjugate
- conjugates
- peptide
- targeting compound
- modified superantigen
- Prior art date
Links
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 231100000617 superantigen Toxicity 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101500027988 Mus musculus ADGRV1 subunit beta Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 231100000655 enterotoxin Toxicity 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9402430A SE9402430L (sv) | 1994-07-11 | 1994-07-11 | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
EP95926057A EP0766566B1 (en) | 1994-07-11 | 1995-06-07 | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
US08/765,695 US7226601B1 (en) | 1994-07-11 | 1995-06-07 | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
RU97102113/13A RU2183215C2 (ru) | 1994-07-11 | 1995-06-07 | Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего |
AT95926057T ATE200626T1 (de) | 1994-07-11 | 1995-06-07 | Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats |
JP50425196A JP4175489B2 (ja) | 1994-07-11 | 1995-06-07 | 改変型超抗原と標的探索化合物との結合体及び該結合体の使用 |
DE69520739T DE69520739T2 (de) | 1994-07-11 | 1995-06-07 | Konjugat aus einem modifizierten superantigen und einer zielsuchenden verbindung und die verwendung des konjugats |
PT95926057T PT766566E (pt) | 1994-07-11 | 1995-06-07 | Um conjugado entre um superantigenio modificado e um composto buscador de alvos e utilizacao do conjugado |
CN95194071A CN1089606C (zh) | 1994-07-11 | 1995-06-07 | 一种修饰的超抗原和一种寻找靶物化合物的缀合物和该缀合物的用途 |
ES95926057T ES2158950T3 (es) | 1994-07-11 | 1995-06-07 | Un conjugado entre un superantigeno modificado y un compuesto buscador de blanco y el uso del conjugado. |
PL95318162A PL180747B1 (pl) | 1994-07-11 | 1995-06-07 | Koniugat przeciwciało-superantygen |
NZ289951A NZ289951A (en) | 1994-07-11 | 1995-06-07 | A conjugate between a modified superantigen and a target seeking compound; use of the conjugate for lysis of cells |
DK95926057T DK0766566T3 (da) | 1994-07-11 | 1995-06-07 | Konjugat mellem et modificeret superantigen og en målsøgende forbindelse samt anvendelse af konjugatet |
HU9700063A HU221254B1 (en) | 1994-07-11 | 1995-06-07 | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
KR1019970700156A KR100377506B1 (ko) | 1994-07-11 | 1995-06-07 | 변이된초항원과표적-탐지화합물간의복합체,이복합체를함유하는제약학적조성물및이를이용한치료방법 |
AU29940/95A AU699147B2 (en) | 1994-07-11 | 1995-06-07 | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
CA002194673A CA2194673C (en) | 1994-07-11 | 1995-06-07 | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
PCT/SE1995/000681 WO1996001650A1 (en) | 1994-07-11 | 1995-06-07 | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
TW084106800A TW413636B (en) | 1994-07-11 | 1995-07-01 | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
IL11444595A IL114445A (en) | 1994-07-11 | 1995-07-04 | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
UA97020534A UA73067C2 (en) | 1994-07-11 | 1995-07-06 | Conjugate between modified superantigene and compound directed to the target |
MYPI95001925A MY112916A (en) | 1994-07-11 | 1995-07-10 | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
ZA955746A ZA955746B (en) | 1994-07-11 | 1995-07-11 | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
FI970100A FI118150B (fi) | 1994-07-11 | 1997-01-10 | Muunnetun superantigeenin ja kohdetta etsivän yhdisteen välinen konjugaatti ja konjugaatin käyttö |
NO19970108A NO320151B1 (no) | 1994-07-11 | 1997-01-10 | Konjugat mellom en biospesifikk affinitetsmotpart og et peptid avledet fra et superantigen som er kovalent bundet til hverandre |
HK98113340A HK1012226A1 (en) | 1994-07-11 | 1998-12-14 | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
GR20010401035T GR3036187T3 (en) | 1994-07-11 | 2001-07-06 | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
US11/193,748 US20050260215A1 (en) | 1994-07-11 | 2005-07-29 | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
US11/193,869 US20060062795A1 (en) | 1994-07-11 | 2005-07-29 | Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9402430A SE9402430L (sv) | 1994-07-11 | 1994-07-11 | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
Publications (2)
Publication Number | Publication Date |
---|---|
SE9402430D0 SE9402430D0 (sv) | 1994-07-11 |
SE9402430L true SE9402430L (sv) | 1996-01-12 |
Family
ID=20394684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE9402430A SE9402430L (sv) | 1994-07-11 | 1994-07-11 | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
Country Status (27)
Country | Link |
---|---|
US (3) | US7226601B1 (xx) |
EP (1) | EP0766566B1 (xx) |
JP (1) | JP4175489B2 (xx) |
KR (1) | KR100377506B1 (xx) |
CN (1) | CN1089606C (xx) |
AT (1) | ATE200626T1 (xx) |
AU (1) | AU699147B2 (xx) |
CA (1) | CA2194673C (xx) |
DE (1) | DE69520739T2 (xx) |
DK (1) | DK0766566T3 (xx) |
ES (1) | ES2158950T3 (xx) |
FI (1) | FI118150B (xx) |
GR (1) | GR3036187T3 (xx) |
HK (1) | HK1012226A1 (xx) |
HU (1) | HU221254B1 (xx) |
IL (1) | IL114445A (xx) |
MY (1) | MY112916A (xx) |
NO (1) | NO320151B1 (xx) |
NZ (1) | NZ289951A (xx) |
PL (1) | PL180747B1 (xx) |
PT (1) | PT766566E (xx) |
RU (1) | RU2183215C2 (xx) |
SE (1) | SE9402430L (xx) |
TW (1) | TW413636B (xx) |
UA (1) | UA73067C2 (xx) |
WO (1) | WO1996001650A1 (xx) |
ZA (1) | ZA955746B (xx) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9402430L (sv) * | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
SE9601245D0 (sv) * | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
AU748097B2 (en) * | 1997-07-21 | 2002-05-30 | Active Biotech Ab | Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents |
DE19827837A1 (de) * | 1998-06-23 | 1999-12-30 | Ernst Gleichmann | Universell an Haupthistokompatibilitätskomplexmoleküle der Klasse II bindende Peptide zur prädiktiven Testung, Diagnostik, Prophylaxe und Therapie von Sensibilisierungen gegen Chemikalen |
US7491402B2 (en) | 1998-12-24 | 2009-02-17 | Auckland Uniservices Limited | Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof |
SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
GB0118155D0 (en) * | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
NZ519371A (en) | 2002-06-04 | 2004-11-26 | Auckland Uniservices Ltd | Immunomodulatory constructs and their uses |
US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US8025873B2 (en) | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
SE0402025D0 (sv) * | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
US20080274133A1 (en) * | 2004-11-18 | 2008-11-06 | Avidex Ltd. | Soluble Bifunctional Proteins |
KR20130108481A (ko) * | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
CN102516392B (zh) * | 2011-11-25 | 2014-05-28 | 孙嘉琳 | 一种癌靶向超抗原融合蛋白及制备方法及用途 |
WO2014025199A2 (ko) * | 2012-08-09 | 2014-02-13 | 주식회사 한독 | 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
WO2017122098A2 (en) | 2016-01-10 | 2017-07-20 | Neotx Therapeutics Ltd. | Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy. |
US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
WO2020013803A1 (en) * | 2018-07-09 | 2020-01-16 | Synthis, Llc | Antibody-alk5 inhibitor conjugates and their uses |
KR20220009428A (ko) | 2019-05-15 | 2022-01-24 | 네오티엑스 테라퓨틱스 엘티디. | 암 치료 |
IL296103A (en) | 2020-03-05 | 2022-11-01 | Neotx Therapeutics Ltd | Methods and preparations for treating cancer with immune cells |
WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627644A (en) | 1968-03-01 | 1971-12-14 | Hajime Okamoto | Process for the cultivation of hemolytic streptococci |
US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
US4268434A (en) | 1979-01-09 | 1981-05-19 | Higerd Thomas B | Immunosuppressive extracellular product from oral bacteria |
US5091091A (en) | 1981-11-06 | 1992-02-25 | Terman David S | Protein A perfusion and post perfusion drug infusion |
US4699783A (en) | 1983-03-11 | 1987-10-13 | Terman David S | Products and methods for treatment of cancer |
US4681870A (en) | 1985-01-11 | 1987-07-21 | Imre Corporation | Protein A-silica immunoadsorbent and process for its production |
IT1192014B (it) | 1986-06-27 | 1988-03-31 | Rubinetterie Mariani Spa | Becco di erogazione per lavabo o simile apparecchio idraulico con comando del salterello |
US4980160A (en) | 1986-10-16 | 1990-12-25 | Biogen, Inc. | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases |
ES2058538T3 (es) | 1988-07-22 | 1994-11-01 | Imre Corp | Compuestos de proteina a purificados y procedimiento para su preparacion. |
SE8903100D0 (sv) | 1989-09-20 | 1989-09-20 | Pharmacia Ab | New pharmaceutical agent |
US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
DE69133484T2 (de) | 1990-01-17 | 2006-05-18 | Terman, David S., Pepple Beach | Verwendung von Staphylococcus-Enterotoxinen oder verwandte Verbindungen für Krebs-Therapie |
JP3334130B2 (ja) * | 1990-07-20 | 2002-10-15 | フアルマシア・アクチエボラーグ | 抗体接合体 |
US6197299B1 (en) * | 1990-07-20 | 2001-03-06 | Pharmacia & Upjohn Ab | Antibody conjugates |
US5858363A (en) * | 1990-07-20 | 1999-01-12 | Pharmacia & Upjohn Ab | Target specific antibody-superantigen conjugates and their preparation |
WO1993024136A1 (en) * | 1991-01-17 | 1993-12-09 | Terman David S | Tumor killing effects of enterotoxins, superantigens, and related compounds |
SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
JPH08500328A (ja) | 1992-01-28 | 1996-01-16 | ナショナル ジューイッシュ センター フォア イミュノロジィ アンド レスパラトリィ メディスン | 突然変異したスーパー抗原の保護作用 |
SE9402430L (sv) * | 1994-07-11 | 1996-01-12 | Pharmacia Ab | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten |
SE9601245D0 (sv) * | 1996-03-29 | 1996-03-29 | Pharmacia Ab | Chimeric superantigens and their use |
TW517061B (en) * | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
-
1994
- 1994-07-11 SE SE9402430A patent/SE9402430L/xx not_active Application Discontinuation
-
1995
- 1995-06-07 RU RU97102113/13A patent/RU2183215C2/ru not_active IP Right Cessation
- 1995-06-07 AU AU29940/95A patent/AU699147B2/en not_active Ceased
- 1995-06-07 DE DE69520739T patent/DE69520739T2/de not_active Expired - Lifetime
- 1995-06-07 JP JP50425196A patent/JP4175489B2/ja not_active Expired - Fee Related
- 1995-06-07 WO PCT/SE1995/000681 patent/WO1996001650A1/en active IP Right Grant
- 1995-06-07 DK DK95926057T patent/DK0766566T3/da active
- 1995-06-07 PL PL95318162A patent/PL180747B1/pl not_active IP Right Cessation
- 1995-06-07 PT PT95926057T patent/PT766566E/pt unknown
- 1995-06-07 CN CN95194071A patent/CN1089606C/zh not_active Expired - Fee Related
- 1995-06-07 EP EP95926057A patent/EP0766566B1/en not_active Expired - Lifetime
- 1995-06-07 ES ES95926057T patent/ES2158950T3/es not_active Expired - Lifetime
- 1995-06-07 AT AT95926057T patent/ATE200626T1/de active
- 1995-06-07 NZ NZ289951A patent/NZ289951A/xx not_active IP Right Cessation
- 1995-06-07 KR KR1019970700156A patent/KR100377506B1/ko not_active IP Right Cessation
- 1995-06-07 US US08/765,695 patent/US7226601B1/en not_active Expired - Fee Related
- 1995-06-07 HU HU9700063A patent/HU221254B1/hu not_active IP Right Cessation
- 1995-06-07 CA CA002194673A patent/CA2194673C/en not_active Expired - Fee Related
- 1995-07-01 TW TW084106800A patent/TW413636B/zh not_active IP Right Cessation
- 1995-07-04 IL IL11444595A patent/IL114445A/xx not_active IP Right Cessation
- 1995-07-06 UA UA97020534A patent/UA73067C2/uk unknown
- 1995-07-10 MY MYPI95001925A patent/MY112916A/en unknown
- 1995-07-11 ZA ZA955746A patent/ZA955746B/xx unknown
-
1997
- 1997-01-10 NO NO19970108A patent/NO320151B1/no not_active IP Right Cessation
- 1997-01-10 FI FI970100A patent/FI118150B/fi not_active IP Right Cessation
-
1998
- 1998-12-14 HK HK98113340A patent/HK1012226A1/xx not_active IP Right Cessation
-
2001
- 2001-07-06 GR GR20010401035T patent/GR3036187T3/el unknown
-
2005
- 2005-07-29 US US11/193,869 patent/US20060062795A1/en not_active Abandoned
- 2005-07-29 US US11/193,748 patent/US20050260215A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE9402430D0 (sv) | Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten | |
ATE267610T1 (de) | Glykosylierte igg antikörper | |
NO20051048L (no) | Terapeutisk humant anti-IL-1R1 monoklonalt antistoff | |
AU3202195A (en) | Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype | |
DE69830492D1 (de) | Antikörper als ARZNEIMITTEL GEGEN LYMPHOCYTISCHE TUMORE (AUSSCHLIESSLICH MYELOME) | |
ATE328611T1 (de) | Multiple,kohlenhydrathaltige glycopeptid-antigene,daraus entwickelte impfstoffe sowie deren verwendung | |
ATE442439T1 (de) | Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren | |
DE69535501D1 (de) | Identifikation, reinigung und verwendungen von leczymen und karbohydratliganden | |
FI945865A (fi) | Glykoprofeiini P:lle kohdistettuja monoklonaalisia vasta-aineita | |
US4902495A (en) | IgE Fc directed delivery system | |
AU641736B2 (en) | Delivery of agents | |
Brunda et al. | Heterogeneity of binding of human IgA subclasses to protein A | |
Givner et al. | Type III group B Streptococcus: functional interaction with IgG subclass antibodies | |
Boquet et al. | Studies on the Role of a Nucleoside‐Phosphate‐Binding Site of Diphtheria Toxin in the Binding of Toxin to Vero Cells or Liposomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NAV | Patent application has lapsed |
Ref document number: 9402430-4 |